Valink Therapeutics has appointed Martin D. Williams as Chair of its Board of Directors and named its Scientific Advisory ...
Teva Pharmaceutical Industries Ltd. ADR 26.47% $18.82B ...
The addition of BIOVECTRA’s biologics capabilities to accelerate drug development and manufacturing will allow Agilent to expand its end-to-end offerings for biopharma services.
a global biopharma company to unite science ... will be the first greenfield pharmaceutical manufacturing site that GSK has built globally over the past ten years. It is also the first facility ...
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of ...
GSK licensed the drug from longstanding partner Ionis as part of a two-drug deal in 2019, paying $25 million upfront with milestone payments taking the value of the deal up to $262 million.
The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Depemokimab (GSK-3511294) is under development for the ...
After hours: December 11 at 6:07:08 PM EST Loading Chart for AYTU ...
adding that GSK needs to effectively make a sweep of its current board and replace them with directors with greater "biopharmaceuticals and scientific experience" – which may be an oblique ...